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Abstract In patients with ischemic cardiomyopa-
thy, coronary artery bypass grafting (CABG) offers
an important therapeutic option but is still associated
with high perioperative mortality. Although previous
studies suggest a beneﬁt from revascularization for
patients with deﬁned viability by a non-invasive
technique, the role of viability assessment to deter-
mine suitability for revascularization in patients with
ischemic cardiomyopathy has not yet been deﬁned.
This study evaluates the hypothesis that the use of
PET imaging in the decision-making process for
CABG will improve postoperative patient survival.
We reviewed 476 patients with ischemic cardiomy-
opathy (LV ejection fraction B0.35) who were
considered candidates for CABG between 1994 and
2004 on the basis of clinical presentation and
angiographic data. In a Standard Care Group, 298
patients underwent CABG. In a second PET-assisted
management group of 178 patients, 152 patients
underwent CABG (PET-CABG) and 26 patients were
excluded from CABG because of lack of viability
(PET-Alternatives). Primary endpoint was postoper-
ative survival. There were two in hospital deaths in
the PET-CABG (1.3%) and 30 (10.1%) in the
Standard Care Group (P = 0.018). The survival rate
after 1, 5 and 9.3 years was 92.0, 73.3 and 54.2% in
the PET-CABG and 88.9, 62.2 and 35.5% in the
Standard Care Group, respectively (P = 0.005). Cox-
regression analysis revealed a signiﬁcant inﬂuence on
long-term survival of patient selection by viability
assessment via PET (P = 0.008), of LV-function
(P = 0.017), and age[70 (P = 0.016). Preoperative
assessment of myocardial viability via PET identiﬁes
patients, who will beneﬁt most from CABG.
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Introduction
In patients with advanced coronary artery disease
(CAD) and severely reduced LV-function, coronary
artery bypass grafting (CABG) offers an important
therapeutic option [1–4] Nevertheless, CABG in this
speciﬁc group of patients is still associated with a
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20% depending on LV-function and severity of
congestive heart failure [2, 4]. On the other hand,
LV function can improve signiﬁcantly after revascu-
larization [5–8]. Clinicians face the difﬁculty to
balance the potential beneﬁt of surgical revascular-
ization with the increased perioperative risk in this
speciﬁc group of patients [9]. In order to improve
mortality, methods are sought to select patients who
may beneﬁt mostly from CABG.
The assessment of myocardial viability by nuclear
imaging techniques has become an important aspect
of the diagnostic and prognostic work-up of patients
with ischemic cardiomyopathy [10–14]. Noninvasive
imaging, such as positron emission tomography
(PET), has been reported to be a useful tool for the
determination of tissue viability and hence for the
prediction of reversibility of regional LV dysfunction
[15]. PET, using nitrogen-13 (N-13) ammonia and
Fluorine-18 ﬂuorodeoxyglucose (F-18 FDG) is a well
established method to further differentiate viable
tissue that may beneﬁt from revascularization from
scarred myocardium [12–13].
Previous studies showed that revascularization of
patients with viability results in an improvement of
heart failure symptoms, and exercise capacity
[16–17]. Patients selected for CABG on the basis of
PET viability studies may also have fewer perioper-
ative complications [18]. A meta-analysis from 2002
including 3,088 patients suggests that the differenti-
ation of viable from nonviable myocardium is also an
important issue in the selection process between
medical therapy versus myocardial revascularization
in heart failure patients [10]. Nevertheless, the role of
viability assessment to determine suitability for
revascularization is still an open question and an
optimal diagnostic protocol in patients with ischemic
cardiomyopathy has not yet been deﬁned. In a recent
study, Beanlands et al. [19] could not demonstrate a
signiﬁcant reduction in cardiac events in patients with
LV-dysfunction and suspected coronary disease for
FDG PET-assisted management versus standard care.
The current study evaluates the hypothesis that the
useofPETimaginginthedecision-makingprocessfor
CABG will improve postoperative patient survival. In
a retrospective study, 476 consecutive patients with
ischemic cardiomyopathy were analyzed who were
referred for CABG between 1994 and 2004. Postop-
erative survival was compared in patients selected for
revascularization on the basis of clinical and angio-
graphic data alone, and patients who underwent a
supplementary myocardial viability testing via PET.
Materials and methods
The current study had the approval of the local Ethic
Committee of the Technische Universitaet Muen-
chen, Munich, Germany, (2370/09). We reviewed
501 consecutive patients with ischemic cardiomyop-
athy (LV ejection fraction B0.35) who were consid-
ered candidates for CABG between 1994 and 2004.
Firstly, 25 patients, who were referred from overseas,
were excluded due to the impossibility of a sufﬁcient
follow-up, and 476 patients were ﬁnally included in
the current study. A standardized questionnaire was
sent to all patients. If no answer ensured, follow-up
was obtained by telephone interview and/or further
information was requested from registry ofﬁces.
Thus, follow-up could be completed in 100% of the
patients. Perioperative complications and mortality
were recorded prospectively as part of an ongoing
quality assurance program. In-hospital mortality was
deﬁned as death within 30 days after operation.
Study groups
Cardiac catheterization was performed in all patients
to assess ventricular function and extent of coronary
artery disease (CAD). Global LV-function was mea-
sured by biplane cine-angiography. The patients who
were candidates for CABG were divided into two
groups (Fig. 1): A Standard Care Group of 298
patients who did not have viability testing preoper-
atively. A second group of 178 patients underwent
PET assisted management: 152 patients had sufﬁcient
viability according to PET and underwent CABG
(PET-CABG), whereas 26 patients had no sufﬁcient
viability and were selected to medical treatment
(n = 18) or transplantation (n = 8).
PET studies
All patients without known diabetes mellitus were
studied in the postprandial state after additional oral
glucose loading with 50 g of glucose. Patients with
known diabetes or abnormal glucose tolerance
received insulin before and during the imaging
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123sequence, according to a standardized protocol [20].
After initial transmission scanning for attenuation
correction,restregionalmyocardialperfusionimaging
with N-13 ammonia (740 MBq) was performed. After
sufﬁcient time for N-13 decay, F-18 FDG (370 MBq)
wasinjected,anddataacquisitionwasinitiated40 min
after tracer injection. Transaxial planes were obtained
using whole-body PET (Siemens CTI 951 or Siemens
Exact 47). Attenuation-corrected transaxial PET
images were generated from N-13 ammonia and
F-18 FDG data. The images were reoriented perpen-
diculartothelongaxisoftheleftventricle,afterwhich
volume-weighted polar maps were calculated from
circumferential proﬁles of the maximal myocardial
activity. In addition, the transaxial image data were
realignedtogenerate images inshort-axis,vertical and
horizontal long-axis views for visual analysis [21].
Regional tracer uptake of N-13 ammonia and F-18
FDG was evaluated visually, by two experienced
observers who had no knowledge of the clinical and
angiographic data, to estimate the extent of necrosis
and viable tissue (Fig. 2). The time between viability
testing and CABG was in all cases less than 3 months.
Viability criteria
Tissue viability by PET was assessed by the
combined interpretation of perfusion and metabolism
within the vascular territories of the left ventricle.
The septal, anterior and anterolateral walls were
considered the vascular territory of the left anterior
descending coronary artery. The left circumﬂex
coronary artery was considered to supply the lateral
and posterolateral walls, whereas the vascular terri-
tory of the right coronary artery was the inferior and
posterior walls. Two different viability criteria were
used: (1) reduced blood ﬂow with preserved or
increased F-18 FDG uptake (mismatch); (2) normal
or near-normal blood ﬂow with normal or increased
F-18 FDG uptake (normal). Reduced blood ﬂow with
reduced F-18 FDG uptake (matched defect) was used
as the criterion for scar (Fig. 2). On the basis of this
visual evaluation, three main criteria were used to
determine whether an individual patient was a
suitable candidate for CABG: (1) The presence of a
‘‘normal or mismatch’’ pattern in akinetic or severely
hypokinetic myocardial areas supplied by a stenosed
or obstructed artery was required. (2) If viable
myocardium was detected in at least two different
vascular territories, we considered the patient an
adequate candidate for CABG, independent of the
estimated target vessel size from the angiographic
report. (3) A large area of scar tissue using an
approximate threshold of 40% was a deciding factor
against CABG. This arbitrary threshold was based on
studies of acute myocardial infarction, that indicated
Baseline diagnostics: Clinical data plus coronary angiography
Sufficient viability   Lack of viability
Alternatives
18                          8     152                                       298
Medical treatment        HTX                    PET-CABG           CABG
PET assisted management Standard Care 
Fig. 1 476 candidates for
CABG 1994-2004. Patients
were selected for CABG on
the basis of clinical
presentation and
angiographic data
(n = 298, Standard Care
Group) or on the basis of an
additional assessment of the
extent of viable tissue by
PET (n = 178). 152
patients of the latter group
underwent CABG (PET-
CABG) and 26 patients
were excluded from CABG
because of lack of viability
(PET-Alternatives) and
either underwent heart
transplantation (n = 8) or
received medical treatment
only (n = 18)
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123a high incidence of cardiogenic shock in infarct areas
[40% of LV mass [22–24]. It was assumed that
patients with a large infarct area are more susceptible
to hemodynamic complications during CABG. The
visually estimated extent of scar tissue was retro-
spectively conﬁrmed by semiquantitative analysis.
Scar tissue was deﬁned as F-18 FDG uptake B50% of
maximal uptake on ‘‘bull’s eye’’ quantitation [25]. On
the basis of the PET criteria, in association with the
angiographic report, 26 patients were found to be
inappropriate candidates for CABG and either under-
went heart transplantation (n = 8) or received only
medical treatment (n = 18).
Statistical analysis
The student t-test for two independent samples and
the chi-squared test were used for continuous and
categorical outcomes, respectively, to evaluate dif-
ferences between the PET-CABG and the Standard
normal                               mismatch               scar 
Metabolism (FDG) 
Reduced wall motion 
Perfusion (NH3) 
Normal        Scar     Mismatch 
Normal     72%  
Scar         16% 
Mismatch 12% 
Fig. 2 PET-Studies and Viability Assessment. Attenuation-
corrected transaxial PET images were generated from N-13
ammonia and F-18 FDG data. The images were reoriented
perpendicular to the long axis of the left ventricle, after which
volume-weighted polar maps were calculated from circumfer-
ential proﬁles of the maximal myocardial activity
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123Care Group. A two-sided P value\0.05 was consid-
ered statistically signiﬁcant. Kaplan–Meier survival
curves were calculated to estimate long-term sur-
vival; differences between groups were assessed with
the log-rank test. Multiple Cox regression analysis
was performed to assess the impact of the following
possible risk factors simultaneously: viability,
LV-function, diabetes, sex and age.
Results
Pre- and intraoperative patient data
Table 1 depicts the main patient characteristics of
both groups. No differences were seen with regard to
preoperative NYHA status, reoperation, diabetes,
the presence of sinus rhythm, preoperative angina,
preoperative creatinine, COPD, or prior myocardial
infarction. Differences were observed regarding
LV-function, age and gender. The PET-CABG exhib-
ited a lower LV-function (PET-CABG: 26.0 ± 6.1,
Standard Care Group: 28.1 ± 5.3; P\0.001; Fig. 2),
a lower percentage of patients[70 years in the PET-
CABG (PET-CABG: 30.3%, Standard Care Group:
39.9%; P = 0.044; Table 1) and the lower percentage
of woman in the PET-CABG (PET-CABG: 10.5%,
Standard Care Group: 17.8%; P = 0.043) as opposed
to the Standard Care Group. 450 patients ﬁnally
underwent CABG, whereas 26 patients were not
selected for revascularization due to insufﬁcient via-
bility as deﬁned previously. 18 patients of these group
received medical treatment and 8 patients underwent
heart transplantation (Fig. 1). No differences were
seen between both groups regarding cardiopulmonary
bypass time (PET-CABG: 103.9 min ± 33.6; Stan-
dard Care Group: 98.8 min ± 31.7; P = 0.128) and
number of coronary anastomoses per patient (PET-
CABG: 3.3 ± 1.0; Standard Care Group: 3.2 ± 0.9;
P = 0.264) .
Follow-up
Mean follow-up was 3.8 years ± 3.02, range from
2 days to 11.07 years (group A: 4.9 ± 2.9, range from
1 day to 10.1 years; group B: 3.3 ± 2.9, range 0.002–
11.1 years; PET-Alternatives: 3.16 ± 3.1, range from
0.02 to 10.9 years) (Fig. 1). Survival analysis was
calculated according to Kaplan–Meier and a log-rank
test was performed (Fig. 1). The log-rank test between
the PET and the Standard Care Group showed also
signiﬁcantdifference(p = 0.0052).There were twoin
hospital deaths in the PET-CABG (1.3%) and 30
(10.1%) in the Standard Care Group (P = 0.018). The
survival rate after 1, 5 and 10 years were in the PET-
CABG 92.0, 73.3 and 54.2% and in the Standard Care
Group88.9,62.2and35.5%,respectively(P = 0.005).
In the group of PET-Alternatives, survival rate was
61.5%(0.8 years), and29.2%(4.8 years).Cox-regres-
sion analysis revealed an inﬂuence of preoperative
Table 1 Pre- and
intraoperative data
Clinical parameter PET-CABG
(n = 152)
Standard Care
Group (n = 298)
P
LVEF 26.0 ± 6.1 28.1 ± 5.3 \0.01
Age 64.0 ± 9.8 66.2 ± 9.3 0.02
Age[70 years 46 (30.3%) 119 (39.9%) 0.04
Female gender 16 (10.5%) 53 (17.8%) 0.04
NYHA III ? IV 136 (89.5%) 279 (93.6%) 0.12
Angina 104 (68.4%) 237 (79.5%) 0.12
Prior myocardial infarction 107 (70.4%) 208 (69.8%) 0.74
Chronic obstructive pulmonary disease 17 (11.2%) 33 (11.1%) 0.79
Preoperative creatinine (mg/dl) 1.29 ± 0.5 1.34 ± 0.8 0.91
Prior cardiac surgery 11 (7.2%) 23 (7.7%) 0.86
Diabetes 60 (39.5%) 111 (37.2%) 0.82
Sinus rhythm 135 (88.8%) 255 (85.6%) 0.34
Cardiopulmonary bypass (minutes) 103.9 ± 33.6 98.8 ± 31.7 0.128
No. anastomoses per patient 3.3 ± 1.0 3.2 ± 0.9 0.264
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123viability assessment via PET (P = 0.008), of preoper-
ative LV-function (P = 0.017), and age [70 (P =
0.016) on long-term survival. Diabetes (P = 0.072)
and female gender (P = 0.085) had no signiﬁcant
inﬂuence (Table 2; Fig. 3).
Discussion
Althoughsurgicalrevascularizationremainsanimpor-
tant therapeutic option in ischemic cardiomyopathy,
these patients face high perioperative mortality when
undergoing CABG that ranges from 4.6 to 20%
depending on LV-function, comorbidities and severity
of congestive heart failure [2, 4, 26]. Previous studies
found a beneﬁt from revascularization for patients
with deﬁned viability by a non-invasive technique, so
that preoperative patient selection by viability testing
has become an issue [10, 11, 21, 27–29].
To assess myocardial viability, different diagnostic
methods are currently performed, i.e. FDG/PET,
MRI, SPECT and echocardiography whereas FDG/
PET is considered the gold-standard due to its ability
to differentiate dysfunctional but viable myocardium
(hibernating myocardium) from scar formation and
normal myocardium [14, 30]. In a multi-centre study
including 157 patients, Gerber et al. [31] showed a
high sensitivity and moderate speciﬁcity of FDG/PET
to predict improvement of cardiac function after
coronary revascularization. The improvement of LV-
function after revascularization seems to be directly
related to the number of dysfunctional but viable
segments, i. e. the mass of viable tissue [32–35].
Furthermore, Tarakji et al. [36] described a strong
association between early revascularization and sur-
vival in a large series of 765 patients who underwent
comprehensive PET imaging.
A meta-analysis from 2002 included 3,088 patients
published in studies examining survival with revas-
cularization versus medical therapy after myocardial
viability testing in patients with ischemic cardiomy-
opathy [10]. Non-invasive imaging techniques
included thallium perfusion imaging, FDG/PET, and
dobutamine echocardiography. Viability was inter-
preted as ‘‘present’’ or ‘‘absent’’ based on individual
study deﬁnitions. The authors found a strong associ-
ation between myocardial viability on noninvasive
testing and improved survival after revascularization
in patients with ischemic cardiomyopathy. Further-
more, it was suggested that the differentiation of
viable from nonviable myocardium could be crucial
in the selection process between medical therapy
versus myocardial revascularization.
Nevertheless, the role of viability assessment to
determine suitability for revascularization is still an
open question and an optimal diagnostic protocol in
patients with ischemic cardiomyopathy has not yet
been deﬁned. Recently, in the PARR-2 study (Pos-
itron emission tomography and recovery following
revascularization), Beanlands et al. included patients
with ischemic cardiomyopathy and randomized the
patients to management assisted by FDG PET
(n = 218) or standard care (n = 212). The study
found a reduction of adverse cardiac events of 36% in
Table 2 Risk assessment for long-term survival (Cox)
Estimated
regression
coefﬁcient
Hazard ratio P
Viability 0.23 1.26 \0.01
LVEF -0.20 0.82 0.02
Diabetes 0.15 1.16 0.07
Female 0.13 1.14 0.09
Age[70 0.20 1.22 0.02
024681 0 1 2
Years
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B: 265 82 9
 C:      16                    5                   
P < 0.00001 
C PET – Alternatives
Fig. 3 Cumulative survival after CABG
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123the standard care arm versus 30% in the PET-assisted
arm that did not reach statistical signiﬁcance [19].
This study has been criticized for the fact, that 25%
patients with PET-indicated revascularization did not
have it done [37]. In the subgroup of patients who
adhered to PET recommendations regarding revascu-
larization, however, signiﬁcant survival beneﬁts were
observed. These ﬁndings are supported by the current
study, in which every patient with sufﬁcient viability
in the PET-assisted group underwent CABG and
exhibited signiﬁcant better mortality rates after
revascularization.
The concept of a preoperative PET-based selection
of patients who beneﬁt mostly from CABG was
examined by Haas et al. [18] who found a signiﬁcant
reduction in perioperative mortality in patient with
deﬁned viability. Subsequent studies indicate that
dysfunctional regions with normal perfusion are more
common than mismatch, have less associated tissue
injury and are more likely to demonstrate complete
recovers than mismatch segments (31 vs. 18%,
respectively) [38–39].
The key ﬁnding of the present study was the
signiﬁcant reduction of the 30-day mortality in
the PET-CABG group with 1.3 versus 10.3% in the
Standard Care group. Despite the improvement of
hospital mortality after CABG in the last years, the
observed early mortality rate of 1.3% in the PET-
CABG group is lower than current reports by the
STICH (Surgical Treatment for Ischemic Heart
Failure) study [3] or the study by Nardi et al. [26],
that reported a hospital mortality of 5 and 5.3%,
respectively. The early survival beneﬁt of the PET-
CABG persists in the long-term as reﬂected by the
superior survival of the PET-CABG over a 10 year
follow-up.
A preoperative selection protocol, based on myo-
cardial viability testing via PET identiﬁes patients
who can undergo CABG with a risk proﬁle that is
comparable to CABG in patients with normal
LV-function. The Standard Care Group did not
undergo a selection process via PET, and presumably
patients with greater unrecognized extent of scar
tissue were not excluded.
The selection process in the present study leads to
a proper identiﬁcation of patients with a lower risk
proﬁle when undergoing CABG. Statistical analysis
revealed the selection process itself as a signiﬁcant
prognostic factor for postoperative survival (Table 2).
FDG/PET offers unique information beside clinical
and angiographic date that leads to improved patient
selection, which subsequently results in improved
postoperative recovery with a low early mortality and
superior long-term survival after CABG. An impor-
tant limitation of this study is its retrospective design.
The preoperative scheduling for viability testing was
based on an intention-to-treat basis, but not in a
prospective, randomized manner, so that a potential
bias cannot be totally excluded.
Previous studies have addressed the issue of patient
selection for revascularization in ischemic cardiomy-
opathy due to the high perioperative risk. Neverthe-
less, former studies lack long-term follow-up as well
as sufﬁcient sample size to analyze potential beneﬁts
of viability testing prior revascularization. Additional
arguments have been discussed: According to sub-
group analysis of the PARR-2 study, the adherence to
PET recommendations remains crucial [19]. In the
PET-assisted group of the current study, PET recom-
mendations were consequently followed in all cases.
Timing of revascularization has become another
issue of recent research [36], suggesting a beneﬁt
from early revascularization. In the current study,
patients were already candidates for CABG when
viability testing was performed and subsequently
every patient of the PET-assisted group underwent
surgery in less than 3 month time after PET.
Furthermore, the results of the current study are in
line with the PARR-1study that found the amount of
scar detected by FDG-PET as a signiﬁcant indepen-
dent predictor of LV function recovery after revas-
cularization [40].
The main limitation of the current study is its
retrospective design. The study included patients with
severe reduction of LV function who were referred
for revascularization. Limited availability of PET and
outside referral prohibited prospective randomization
of patients in this study. Although a randomization
protocol would have been ideal, careful retrospective
analysis of risk factors was performed in both groups
to identify any selection bias. The decision for an
additional viability testing was made by the respon-
sible surgeon. Both groups suffer equally from angina
and are in NYHA III ? IV (Table 1). Important risk
factors for perioperative mortality, such as preoper-
ative renal function, diabetes, prior myocardial
infarction, chronic obstructive pulmonary disease,
prior cardiac surgery or diabetes are comparable in
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123both groups (Table 1). Furthermore, intraoperative
parameters like cardiopulmonary bypass time or the
number of anastomoses per patient did not differ
between the two groups. Only small differences
between the two groups were seen in LVEF, age, and
gender (Table 1).
The present study did not compare FDG-PET with
other imaging modalities for detection of viable
myocardium. Further studies are necessary to deter-
mine whether the same results may be obtained with
conventional scintigraphic techniques, such as thal-
lium-201 imaging, magnetic resonance imaging or
low dose dobutamine echocardiography.
Nevertheless, the cut-off point of 40% of scar
tissue for the indication for CABG, which was
applied in the present study, represents an arbitrary
threshold. This arbitrary threshold was based on
studies of acute myocardial infarction that indicated a
higher incidence of cardiogenic shock in infarct areas
averaging 37, 43 and 51% of LV mass [22–24] which
may indicate an irreversible condition. Yoshida et al.
[24] showed that the size of the infarct area and
viability in arterial zones at risk assessed by PET are
good prognostic markers for mortality. In their study,
6 of 35 patients had an infarct size between 39 and
77%, as determined by quantitative PET measure-
ments. Four of these patients died within a 3-year
period, three of them after revascularization.
As the present study showed, the criterion of scar
extent alone is not sufﬁcient for the selection process
in some patients. Four patients in the PET-CABG
exhibited a scar tissue area C40%. However, in these
patients the other main viability criteria and the
angiographic report supported the decision, that these
patients were adequate candidates for CABG. Two of
the patients are still alive (follow-up time: 6.7 and
7.7 years). In both patients, PET revealed high
percentages of viable myocardium: 40–45% scar,
52–60% viable myocardium and 0–3% mismatch. A
third patient died 8 months after surgery (PET: 46%
scar, 5% mismatch and 49% viable myocardium), and
the fourth patient died 3.9 years after CABG (PET:
43% scar, 10% mismatch, 47% viable myocardium).
These ﬁndings underscore the complexity of decision
making in this speciﬁc group of patients. Neverthe-
less, only four patients of 178 patients (2.24%), who
underwent preoperative PET management, did not
totally apply to the exclusion criterion by PET.
Therefore, we suggest that in patients with a scar
tissue area of around 40%, the 40% cut-off point
should not be strictly applied but appreciated in
request to the other viability criteria as well as
angiographic results.
Conclusions
In ischemic cardiomyopathy, patient selection by
preoperative viability testing via PET leads to a
signiﬁcant reduction of perioperative mortality rates
after surgical revascularization. This survival beneﬁt
persists in the long-term. Prospective, randomized are
necessary to further evaluate the impact of preoper-
ative viability assessment in this high risk group of
patients.
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